Deutsche Bank Initiates Coverage of LS/Dx Sector; Gives Fluidigm, Thermo Fisher, Myriad Buy Ratings | GenomeWeb

NEW YORK (GenomeWeb) – Deutsche Bank has initiated coverage on the life sciences and diagnostics sector, saying it is "generally positive" on the outlook for its fundamentals, even though company valuations are near historical highs, and assigned a Neutral outlook for the group of eight stocks.

Analyst Shawn Bevec assigned Buy ratings to shares of Fluidigm, Myriad Genetics, and Thermo Fisher Scientific, and Hold ratings to shares of Agilent Technologies, Bruker, Illumina, PerkinElmer, and Waters. He also listed Myriad and Thermo Fisher as "top" picks.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.